HC Wainwright Reiterates “Neutral” Rating for Chimerix (NASDAQ:CMRX)

Chimerix (NASDAQ:CMRX)‘s stock had its “neutral” rating reiterated by HC Wainwright in a note issued to investors on Wednesday,Benzinga reports. They currently have a $8.55 target price on the biopharmaceutical company’s stock, down from their previous target price of $11.00. HC Wainwright’s target price would suggest a potential upside of 1.42% from the company’s current price.

Separately, Wedbush reissued an “outperform” rating and issued a $7.00 price target (up previously from $6.00) on shares of Chimerix in a research report on Tuesday, February 18th.

Chimerix Stock Down 0.4 %

CMRX stock opened at $8.43 on Wednesday. Chimerix has a twelve month low of $0.75 and a twelve month high of $8.47. The company has a market cap of $758.16 million, a PE ratio of -8.97 and a beta of 0.32. The business’s 50-day simple moving average is $4.14 and its 200 day simple moving average is $2.21.

Insider Transactions at Chimerix

In related news, CEO Michael T. Andriole sold 7,370 shares of Chimerix stock in a transaction dated Thursday, February 13th. The stock was sold at an average price of $4.52, for a total value of $33,312.40. Following the completion of the sale, the chief executive officer now directly owns 609,603 shares in the company, valued at $2,755,405.56. This trade represents a 1.19 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders sold a total of 20,760 shares of company stock worth $91,175 over the last 90 days. 13.10% of the stock is owned by insiders.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. Deerfield Management Company L.P. Series C bought a new stake in shares of Chimerix during the fourth quarter worth approximately $13,124,000. Rosalind Advisors Inc. acquired a new stake in Chimerix during the 4th quarter worth $10,614,000. Boxer Capital Management LLC acquired a new stake in Chimerix during the 4th quarter worth $7,169,000. Marshall Wace LLP raised its position in shares of Chimerix by 1,318.5% during the 4th quarter. Marshall Wace LLP now owns 2,213,940 shares of the biopharmaceutical company’s stock valued at $7,705,000 after acquiring an additional 2,057,864 shares during the last quarter. Finally, Peapod Lane Capital LLC acquired a new position in shares of Chimerix in the 4th quarter valued at $2,626,000. Institutional investors own 45.42% of the company’s stock.

Chimerix Company Profile

Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.